Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04003610
Title Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Incyte Corporation
Indications

transitional cell carcinoma

Therapies

Pembrolizumab + Pemigatinib

Pembrolizumab

Carboplatin + Gemcitabine

Pemigatinib

Age Groups: senior | adult
Covered Countries USA | CAN

Additional content available in CKB BOOST